よむ、つかう、まなぶ。
資料２－５ 重篤副作用疾患別対応マニュアル 進行性多巣性白質脳症（PML）（案） (24 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000209243_00004.html |
| 出典情報 | 重篤副作用総合対策検討会（第14回 9／15）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
results in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. JAMA
Neurol 2018;75:827–833.
16) Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused
by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425–437.
17) Mass RP, Muller-Hansman A, Esselink R, et al. Drug-associated progressive multifocal
leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J
Neurol 2016;263:2004–2021.
18) 岸田修二. PML の疫学と臨床. Brain Nerve 2007;59:125–137.
19) Richardson-Burns SM, Kleinschmidt-DeMasters BK, DeBiasi RL, et al. Progressive
multifocal leukoencephalopathy and apoptosis of infected oligodendrocytes in the central
nervous system of patients with and without AIDS. Arch Neurol 2002;59:1930–1936.
20) Wollebo HS, White MK, Gordon J, et al. Persistence and pathogenesis of the neurotropic
polyomavirus JC. Ann Neurol 2015;77:560–570.
21) Du Pasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association
22)
23)
24)
25)
26)
27)
28)
between JCPyVirus-specific cytotoxic T lymphocytes and the early control of progressive
multifocal leukoencephalopathy. Brain 2004;127:1970–1978.
Sanjo N, Kina S, Shishido-Hara Y, et al. Progressive multifocal leukoencephalopathy with
balanced CD4/CD8 T-cell infiltration and good response to mefloquine treatment. Intern Med
2016;55:1631–1635.
Landi D, De Rossi N, Zagaglia S, et al. No evidence of beneficial effects of plasmapheresis in
natalizumab-associated PML. Neurology 2017;88:1144–1152.
Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of
mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother
2009;53:1840–1849.
Clifford DB, Nath A, Cinque P, et al. A study of mefloquine treatment for progressive
multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J
Neurovirol 2013;19:351-358.
Diotti RA, Nakanishi A, Clementi N, et al. JC polyomavirus (JCV) and monoclonal
antibodies: friends or potential foes? Clin Dev Immunol 2013;2013:967581.
Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in
natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol
2012;72:779–787.
Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in
natalizumab-associated PML. Neurology 2011;77:1061–1067.
23
Neurol 2018;75:827–833.
16) Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused
by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425–437.
17) Mass RP, Muller-Hansman A, Esselink R, et al. Drug-associated progressive multifocal
leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J
Neurol 2016;263:2004–2021.
18) 岸田修二. PML の疫学と臨床. Brain Nerve 2007;59:125–137.
19) Richardson-Burns SM, Kleinschmidt-DeMasters BK, DeBiasi RL, et al. Progressive
multifocal leukoencephalopathy and apoptosis of infected oligodendrocytes in the central
nervous system of patients with and without AIDS. Arch Neurol 2002;59:1930–1936.
20) Wollebo HS, White MK, Gordon J, et al. Persistence and pathogenesis of the neurotropic
polyomavirus JC. Ann Neurol 2015;77:560–570.
21) Du Pasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association
22)
23)
24)
25)
26)
27)
28)
between JCPyVirus-specific cytotoxic T lymphocytes and the early control of progressive
multifocal leukoencephalopathy. Brain 2004;127:1970–1978.
Sanjo N, Kina S, Shishido-Hara Y, et al. Progressive multifocal leukoencephalopathy with
balanced CD4/CD8 T-cell infiltration and good response to mefloquine treatment. Intern Med
2016;55:1631–1635.
Landi D, De Rossi N, Zagaglia S, et al. No evidence of beneficial effects of plasmapheresis in
natalizumab-associated PML. Neurology 2017;88:1144–1152.
Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of
mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother
2009;53:1840–1849.
Clifford DB, Nath A, Cinque P, et al. A study of mefloquine treatment for progressive
multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J
Neurovirol 2013;19:351-358.
Diotti RA, Nakanishi A, Clementi N, et al. JC polyomavirus (JCV) and monoclonal
antibodies: friends or potential foes? Clin Dev Immunol 2013;2013:967581.
Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in
natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol
2012;72:779–787.
Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in
natalizumab-associated PML. Neurology 2011;77:1061–1067.
23